RESUMEN
Human immunodeficiency virus (HIV-1) depends upon host-encoded proteins to facilitate its replication while at the same time inhibiting critical components of innate and/or intrinsic immune response pathways. To characterize the host cell response on protein levels in CD4+ lymphoblastoid SUP-T1 cells after infection with HIV-1 strain LAI, we used mass spectrometry (MS)-based global quantitation with iTRAQ (isobaric tag for relative and absolute quantification). We found 266, 60 and 22 proteins differentially expressed (DE) (P-value ≤ 0.05) at 4, 8, and 20 hours post-infection (hpi), respectively, compared to time-matched mock-infected samples. The majority of changes in protein abundance occurred at an early stage of infection well before the de novo production of viral proteins. Functional analyses of these DE proteins showed enrichment in several biological pathways including protein synthesis, cell proliferation, and T-cell activation. Importantly, these early changes before the time of robust viral production have not been described before.
Asunto(s)
Linfocitos T CD4-Positivos/química , Infecciones por VIH/genética , VIH-1/fisiología , Proteómica , Linfocitos T/química , Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/virología , Línea Celular , Proliferación Celular , Redes Reguladoras de Genes , Infecciones por VIH/inmunología , Infecciones por VIH/fisiopatología , Infecciones por VIH/virología , VIH-1/genética , Interacciones Huésped-Patógeno , Humanos , Biosíntesis de Proteínas , Linfocitos T/inmunología , Linfocitos T/metabolismo , Linfocitos T/virologíaRESUMEN
UNLABELLED: Liver transplant tissues offer the unique opportunity to model the longitudinal protein abundance changes occurring during hepatitis C virus (HCV)-associated liver disease progression in vivo. In this study, our goal was to identify molecular signatures, and potential key regulatory proteins, representative of the processes influencing early progression to fibrosis. We performed global protein profiling analyses on 24 liver biopsy specimens obtained from 15 HCV(+) liver transplant recipients at 6 and/or 12 months posttransplantation. Differentially regulated proteins associated with early progression to fibrosis were identified by analysis of the area under the receiver operating characteristic curve. Analysis of serum metabolites was performed on samples obtained from an independent cohort of 60 HCV(+) liver transplant patients. Computational modeling approaches were applied to identify potential key regulatory proteins of liver fibrogenesis. Among 4,324 proteins identified, 250 exhibited significant differential regulation in patients with rapidly progressive fibrosis. Patients with rapid fibrosis progression exhibited enrichment in differentially regulated proteins associated with various immune, hepatoprotective, and fibrogenic processes. The observed increase in proinflammatory activity and impairment in antioxidant defenses suggests that patients who develop significant liver injury experience elevated oxidative stresses. This was supported by an independent study demonstrating the altered abundance of oxidative stress-associated serum metabolites in patients who develop severe liver injury. Computational modeling approaches further highlight a potentially important link between HCV-associated oxidative stress and epigenetic regulatory mechanisms impacting on liver fibrogenesis. CONCLUSION: Our proteome and metabolome analyses provide new insights into the role for increased oxidative stress in the rapid fibrosis progression observed in HCV(+) liver transplant recipients. These findings may prove useful in prognostic applications for predicting early progression to fibrosis.
Asunto(s)
Hepacivirus/metabolismo , Hepatitis C/complicaciones , Cirrosis Hepática/patología , Trasplante de Hígado/patología , Análisis por Matrices de Proteínas/métodos , Proteoma/metabolismo , Adulto , Anciano , Biopsia con Aguja , Cromatografía Liquida/métodos , Estudios de Cohortes , Diagnóstico por Computador/métodos , Progresión de la Enfermedad , Femenino , Rechazo de Injerto , Supervivencia de Injerto , Hepacivirus/patogenicidad , Hepatitis C/patología , Humanos , Inmunohistoquímica , Cirrosis Hepática/etiología , Cirrosis Hepática/cirugía , Trasplante de Hígado/efectos adversos , Masculino , Espectrometría de Masas/métodos , Persona de Mediana Edad , Estrés Oxidativo/fisiología , Proteoma/genética , Proteómica/métodos , Recurrencia , Valores de Referencia , Medición de Riesgo , Muestreo , Sensibilidad y EspecificidadRESUMEN
UNLABELLED: Liver failure resulting from chronic hepatitis C virus (HCV) infection is a major cause for liver transplantation worldwide. Recurrent infection of the graft is universal in HCV patients after transplant and results in a rapid progression to severe fibrosis and end-stage liver disease in one third of all patients. No single clinical variable, or combination thereof, has, so far, proven accurate in identifying patients at risk of hepatic decompensation in the transplant setting. A combination of longitudinal, dimensionality reduction and categorical analysis of the transcriptome from 111 liver biopsy specimens taken from 57 HCV-infected patients over time identified a molecular signature of gene expression of patients at risk of developing severe fibrosis. Significantly, alterations in gene expression occur before histologic evidence of liver disease progression, suggesting that events that occur during the acute phase of infection influence patient outcome. Additionally, a common precursor state for different severe clinical outcomes was identified. CONCLUSION: Based on this patient cohort, incidence of severe liver disease is a process initiated early during HCV infection of the donor organ. The probable cellular network at the basis of the initial transition to severe liver disease was identified and characterized.
Asunto(s)
Rechazo de Injerto/genética , Hepatitis C Crónica/complicaciones , Fallo Hepático/cirugía , Trasplante de Hígado/efectos adversos , Activación Transcripcional/genética , Anciano , Biopsia con Aguja , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Regulación de la Expresión Génica , Hepacivirus/genética , Hepacivirus/fisiología , Hepatitis C Crónica/patología , Hepatitis C Crónica/cirugía , Humanos , Inmunohistoquímica , Fallo Hepático/etiología , Fallo Hepático/genética , Trasplante de Hígado/métodos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/genética , Complicaciones Posoperatorias/fisiopatología , Pronóstico , Recurrencia , Medición de Riesgo , Índice de Severidad de la Enfermedad , Donantes de TejidosRESUMEN
PURPOSE: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. EXPERIMENTAL DESIGN: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. RESULTS: In total, 18,880 unique peptides were identified (PeptideProphet peptide error rate ≤1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. CONCLUSIONS AND CLINICAL RELEVANCE: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for multiple reaction monitoring-MS. The availability of these datasets will contribute positively to clinical proteomics.
Asunto(s)
Neoplasias de la Mama/genética , Modelos Animales de Enfermedad , Perfilación de la Expresión Génica , Proteoma/análisis , Proteoma/genética , Receptor ErbB-2/genética , Transcripción Genética/genética , Animales , Bases de Datos de Proteínas , Ratones , Ratones Transgénicos , Proteómica , Receptor ErbB-2/análisis , Espectrometría de Masas en TándemRESUMEN
PURPOSE: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis. MATERIALS AND METHODS: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. RESULTS: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis. CONCLUSION: Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.
Asunto(s)
Proteínas 14-3-3/inmunología , Adenocarcinoma/inmunología , Anexina A1/inmunología , Autoanticuerpos/sangre , Neoplasias Pulmonares/inmunología , Adenocarcinoma/diagnóstico , Estudios de Casos y Controles , Línea Celular Tumoral , Diagnóstico Precoz , Humanos , Neoplasias Pulmonares/diagnóstico , Valor Predictivo de las Pruebas , Análisis por Matrices de Proteínas , Receptores de Laminina/inmunología , Reproducibilidad de los Resultados , Proteínas Ribosómicas , Ubiquitina Tiolesterasa/inmunologíaRESUMEN
BACKGROUND: The complexity and heterogeneity of the human plasma proteome have presented significant challenges in the identification of protein changes associated with tumor development. Refined genetically engineered mouse (GEM) models of human cancer have been shown to faithfully recapitulate the molecular, biological, and clinical features of human disease. Here, we sought to exploit the merits of a well-characterized GEM model of pancreatic cancer to determine whether proteomics technologies allow identification of protein changes associated with tumor development and whether such changes are relevant to human pancreatic cancer. METHODS AND FINDINGS: Plasma was sampled from mice at early and advanced stages of tumor development and from matched controls. Using a proteomic approach based on extensive protein fractionation, we confidently identified 1,442 proteins that were distributed across seven orders of magnitude of abundance in plasma. Analysis of proteins chosen on the basis of increased levels in plasma from tumor-bearing mice and corroborating protein or RNA expression in tissue documented concordance in the blood from 30 newly diagnosed patients with pancreatic cancer relative to 30 control specimens. A panel of five proteins selected on the basis of their increased level at an early stage of tumor development in the mouse was tested in a blinded study in 26 humans from the CARET (Carotene and Retinol Efficacy Trial) cohort. The panel discriminated pancreatic cancer cases from matched controls in blood specimens obtained between 7 and 13 mo prior to the development of symptoms and clinical diagnosis of pancreatic cancer. CONCLUSIONS: Our findings indicate that GEM models of cancer, in combination with in-depth proteomic analysis, provide a useful strategy to identify candidate markers applicable to human cancer with potential utility for early detection.
Asunto(s)
Biomarcadores de Tumor/sangre , Neoplasias Pancreáticas/diagnóstico , Proteoma/metabolismo , Animales , Humanos , Espectrometría de Masas , Ratones , Neoplasias Pancreáticas/sangre , Proteómica/métodos , ARN Mensajero/metabolismoRESUMEN
We developed a visualization approach for the identification of protein isoforms, precursor/mature protein combinations, and fragments from LC-MS/MS analysis of multidimensional fractionation of serum and plasma proteins. We also describe a pattern recognition algorithm to automatically detect and flag potentially heterogeneous species of proteins in proteomic experiments that involve extensive fractionation and result in a large number of identified serum or plasma proteins in an experiment. Examples are given of proteins with known isoforms that validate our approach and present a subset of precursor/mature protein pairs that were detected with this approach. Potential applications include identification of differentially expressed isoforms in disease states.
Asunto(s)
Proteínas Sanguíneas/análisis , Cromatografía Liquida/métodos , Proteoma/análisis , Espectrometría de Masas en Tándem/métodos , Algoritmos , Proteínas Sanguíneas/química , Proteínas Sanguíneas/aislamiento & purificación , Proteínas de Unión al Calcio/análisis , Proteínas de Unión al Calcio/química , Cromatografía Líquida de Alta Presión , Cromatografía por Intercambio Iónico , Humanos , Reconocimiento de Normas Patrones Automatizadas , Fragmentos de Péptidos/análisis , Fragmentos de Péptidos/química , Fosfatidilcolina-Esterol O-Aciltransferasa/análisis , Fosfatidilcolina-Esterol O-Aciltransferasa/química , Isoformas de Proteínas/análisis , Isoformas de Proteínas/química , Isoformas de Proteínas/aislamiento & purificación , Proteoma/química , Proteómica/métodos , Protrombina/análisis , Protrombina/química , Serina Endopeptidasas/análisis , Serina Endopeptidasas/química , Tripsina/químicaRESUMEN
We have implemented a strategy to identify tumor antigens that induce a humoral immune response in lung cancer based on the analysis of tumor cell proteins. Chromatographically fractionated protein extracts from three lung cancer cell lines were subjected to Western blotting and hybridization with individual sera to determine serum antibody binding. Two sets of sera were initially investigated. One set consisted of sera from 19 newly diagnosed subjects with lung adenocarcinoma and 19 matched controls. A second independent set consisted of sera from 26 newly diagnosed subjects with lung adenocarcinoma and 24 controls matched for age, gender, and smoking history. One protein that exhibited significant reactivity with both sets of cancer sera (P = 0.0008) was confidently identified by mass spectrometry as 14-3-3 theta. Remarkably, significant autoantibody reactivity against 14-3-3 theta was also observed in an analysis of a third set consisting of 18 prediagnostic lung cancer sera collected as part of the Beta-Carotene and Retinol Efficacy Trial cohort study, relative to 19 matched controls (P = 0.0042). A receiver operating characteristic curve constructed with a panel of three proteins consisting of 14-3-3 theta identified in this study, plus annexin 1 and protein gene product 9.5 proteins previously identified as associated with autoantibodies in lung cancer, gave a sensitivity of 55% at 95% specificity (area under the curve, 0.838) in discriminating lung cancer at the preclinical stage from matched controls.
Asunto(s)
Proteínas 14-3-3/análisis , Adenocarcinoma/inmunología , Formación de Anticuerpos , Antígenos de Neoplasias/inmunología , Autoanticuerpos/inmunología , Biomarcadores de Tumor/análisis , Biomarcadores/análisis , Neoplasias Pulmonares/inmunología , Proteínas 14-3-3/química , Proteínas 14-3-3/inmunología , Antígenos de Neoplasias/química , Antígenos de Neoplasias/aislamiento & purificación , Biomarcadores/química , Biomarcadores de Tumor/química , Biomarcadores de Tumor/inmunología , Línea Celular Tumoral , Electroforesis en Gel Bidimensional , Electroforesis en Gel de Poliacrilamida , Humanos , Espectrometría de Masas , Valores de ReferenciaRESUMEN
In this study, gene expression profiling was performed on 103 neuroblastoma (NB) tumors, stages 1-4 with and without MYCN amplification, using cDNA microarrays containing 42,578 elements. Using principal component analysis (PCA) to analyse the relationships among these samples, we confirm that the global patterns of gene expression reflect the phenotype of the tumors. To explore the biological processes that may contribute to increasing aggressive phenotype of the tumors, we utilized a statistical approach based on PCA. We identified a specific subset of the cell cycle and/or chromosome segregation genes that distinguish stage 4 NB tumors from all lower stage tumors, including stage 3. Furthermore, the control of the kinetochore assembly emerges from the Gene Ontology analysis as one of the key biological processes associated with an aggressive NB phenotype. Finally, we establish that these genes are further upregulated in the most aggressive MYCN-amplified tumors.
Asunto(s)
Ciclo Celular/genética , Regulación Neoplásica de la Expresión Génica , Neuroblastoma/genética , Segregación Cromosómica/genética , Cromosomas Humanos/genética , Perfilación de la Expresión Génica , Genes myc , Humanos , Estadificación de Neoplasias , Neuroblastoma/patología , Análisis de Secuencia por Matrices de Oligonucleótidos , FenotipoRESUMEN
Currently, patients with neuroblastoma are classified into risk groups (e.g., according to the Children's Oncology Group risk-stratification) to guide physicians in the choice of the most appropriate therapy. Despite this careful stratification, the survival rate for patients with high-risk neuroblastoma remains <30%, and it is not possible to predict which of these high-risk patients will survive or succumb to the disease. Therefore, we have performed gene expression profiling using cDNA microarrays containing 42,578 clones and used artificial neural networks to develop an accurate predictor of survival for each individual patient with neuroblastoma. Using principal component analysis we found that neuroblastoma tumors exhibited inherent prognostic specific gene expression profiles. Subsequent artificial neural network-based prognosis prediction using expression levels of all 37,920 good-quality clones achieved 88% accuracy. Moreover, using an artificial neural network-based gene minimization strategy in a separate analysis we identified 19 genes, including 2 prognostic markers reported previously, MYCN and CD44, which correctly predicted outcome for 98% of these patients. In addition, these 19 predictor genes were able to additionally partition Children's Oncology Group-stratified high-risk patients into two subgroups according to their survival status (P = 0.0005). Our findings provide evidence of a gene expression signature that can predict prognosis independent of currently known risk factors and could assist physicians in the individual management of patients with high-risk neuroblastoma.
Asunto(s)
Perfilación de la Expresión Génica/métodos , Redes Neurales de la Computación , Neuroblastoma/genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Preescolar , Terapia Combinada , Humanos , Lactante , Neuroblastoma/tratamiento farmacológico , Neuroblastoma/metabolismo , Neuroblastoma/cirugía , Análisis de Secuencia por Matrices de Oligonucleótidos , Valor Predictivo de las Pruebas , Análisis de Componente Principal , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
BACKGROUND: Recurrent non-random genomic alterations are the hallmarks of cancer and the characterization of these imbalances is critical to our understanding of tumorigenesis and cancer progression. RESULTS: We performed array-comparative genomic hybridization (A-CGH) on cDNA microarrays containing 42,000 elements in neuroblastoma (NB). We found that only two chromosomes (2p and 12q) had gene amplifications and all were in the MYCN amplified samples. There were 6 independent non-contiguous amplicons (10.4-69.4 Mb) on chromosome 2, and the largest contiguous region was 1.7 Mb bounded by NAG and an EST (clone: 757451); the smallest region was 27 Kb including an EST (clone: 241343), NCYM, and MYCN. Using a probabilistic approach to identify single copy number changes, we systemically investigated the genomic alterations occurring in Stage 1 and Stage 4 NBs with and without MYCN amplification (stage 1-, 4-, and 4+). We have not found genomic alterations universally present in all (100%) three subgroups of NBs. However we identified both common and unique patterns of genomic imbalance in NB including gain of 7q32, 17q21, 17q23-24 and loss of 3p21 were common to all three categories. Finally we confirm that the most frequent specific changes in Stage 4+ tumors were the loss of 1p36 with gain of 2p24-25 and they had fewer genomic alterations compared to either stage 1 or 4-, indicating that for this subgroup of poor risk NB requires a smaller number of genomic changes are required to develop the malignant phenotype. CONCLUSIONS: cDNA A-CGH analysis is an efficient method for the detection and characterization of amplicons. Furthermore we were able to detect single copy number changes using our probabilistic approach and identified genomic alterations specific to stage and MYCN amplification.